The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around the mechanism of action of MCO-010, the results of the RESTORE trial and what the next steps in clinical development of MOC-010 is.
The presentation entitled ‘Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)’ was presented at the Association for Research in Vision and Ophthalmology Annual Meeting, May 05-09, 2023
Questions:
What is MCO-010 and what is its mechanism of action? (0:19)
What are the aims, design, and eligibility criteria of the RESTORE study? (1:18)
What were the efficacy and safety findings? (2:37)
What will be the next steps in the clinical development of MCO-010? (3:38)
Disclosures: David Boyer has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ARVO 2023.
